Garvin Davis, MD
Retina Specialist · Houston, TXNPI 1154480382
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (50.1%), food and beverage and speaking fees — rather than concentrated in one kind of arrangement. 25 manufacturers reported payments, led by Genentech USA, Inc. at 36.1% of the total. Reporting peaked in 2023 at $13,529 and has fallen 78.4% since, to $2,929 in 2025. Among retina specialist clinicians in TX with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 140 payments — averaging $271.73 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Genentech USA, Inc.$14K
- Alimera Sciences, Inc.$10K
- Bausch & Lomb, A Division Of Bausch Health US, LLC$7K
- AbbVie$2K
- Samsara Vision$1K
- Regeneron Healthcare Solutions, Inc.$1K
- plus $2K from 19 others
What the payments were for
- Consulting fees$19,05050%
- Speaking & faculty fees$8,40022%
- Travel & lodging$1,9705%
- Food & beverage$8,62223%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Genentech USA, Inc. | 19 | $13,727 |
| Alimera Sciences, Inc. | 21 | $10,069 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 13 | $7,210 |
| AbbVie(2 entities) | 12 | $2,364 |
| Samsara Vision | 9 | $1,202 |
| Regeneron Healthcare Solutions, Inc. | 16 | $1,024 |
| Apellis Pharmaceuticals, Inc. | 10 | $671 |
| Bausch & Lomb Americas Inc. | 10 | $457 |
| Novartis | 6 | $266 |
| ANI Pharmaceuticals, Inc. | 2 | $200 |
| Sanofi-aventis U.S. LLC | 2 | $164 |
| Astellas Pharma US Inc | 2 | $159 |
| Amgen(2 entities) | 3 | $152 |
| Novo Nordisk | 1 | $65 |
| UCB, Inc. | 2 | $48 |
| Sun Pharmaceutical Industries Inc. | 2 | $44 |
| Dutch Ophthalmic, USA | 1 | $41 |
| Oyster Point Pharma, Inc. | 2 | $37 |
| Dompe US, Inc. | 1 | $30 |
| Regeneron | 1 | $27 |
| Ocular Therapeutix, Inc. | 1 | $23 |
| The Cameron-ehlen Group, Inc. | 1 | $20 |
| Biotissue Holdings Inc. | 1 | $15 |
| Johnson & Johnson Surgical Vision, Inc. | 1 | $14 |
| Eyepoint US, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$38,042 in reported general payments places this provider in the 90th percentile of 108 retina specialist providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Prednisolone Acetate | 92 | $4,181 |
| ProlensaBromfenac Sodium | 11 | $3,979 |
| Ketorolac Tromethamine | 28 | $749 |
| Brimonidine Tartrate | 31 | $691 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 49 | $619 |
| Latanoprost | 37 | $313 |
| Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha | 11 | $142 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Bausch & Lomb, A Division Of Bausch Health US, LLCProlensa | $7,210 | $3,97911 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 108 retina specialist providers in Texas.
Other retina specialist in Houston
- Ella LeungHouston$12K
- Lindsey HarrisHouston$10K
- Petros CarvounisHouston$8K
- Keith BourgeoisHouston$7K
- Richard FishHouston$5K
- Lee TranHouston$4K
- Michael LamHouston$4K
- John AlappattHouston$4K
- Sapa PhamHouston$4K
- Jie GaoHouston$3K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.